Fig. 1

Effect of Isoliquiritigenin on human aortic smooth muscle cell expansion. a After incubation with various concentrations of ISL for 48 h, HASMCs cell viability was examined by CCK-8 assay. b HASMCs were treated with ISL (10 μM) for different time points and the cell viability was detected by cck8 assay. c HASMCs were treated with ISL (10 μM) for 48 h and cell death was determined by PI staining. All values represented as mean ± SD, n = 5, **: P < 0.01; ***: P < 0.001 compared with untreated HASMCs. #: P < 0.05; ##: P < 0.01, for (a) compared with 10 μM ISL treated HASMCs; for (b) compared with ISL treated HASMCs for 24 h. &: P < 0.05 compared with ISL treated HASMCs for 48 h